ARA-290 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
ARA-290 is one of the most discussed peptides in the research community, with reports focusing on its effects on neuropathic pain relief, inflammation reduction, nerve fiber regeneration, improved autonomic function, metabolic control in diabetes. Clinical trials in sarcoidosis-associated small fiber neuropathy and type 2 diabetes showed significant pain reduction and nerve regeneration. A 28-day protocol initiated measurable corneal nerve fiber regrowth. Chronic stress studies showed antidepressant effects comparable to fluoxetine. 4+ completed clinical trials in humans.
What Do Researchers Report About ARA-290?
ARA-290 (Erythropoietin-derived tissue-protective peptide) is one of the most discussed Innate repair receptor agonist, anti-inflammatory peptide compounds in the peptide research community. Reports span effects on neuropathic pain relief, inflammation reduction, nerve fiber regeneration, improved autonomic function, metabolic control in diabetes.
Clinical trials in sarcoidosis-associated small fiber neuropathy and type 2 diabetes showed significant pain reduction and nerve regeneration. A 28-day protocol initiated measurable corneal nerve fiber regrowth. Chronic stress studies showed antidepressant effects comparable to fluoxetine. 4+ completed clinical trials in humans.
What Are the Most Common Positive Reports?
Researchers frequently cite ARA-290's effects on neuropathic pain relief, inflammation reduction, nerve fiber regeneration, improved autonomic function, metabolic control in diabetes as the primary benefits observed during standard cycles of 28 days typical; 8-16 weeks for extended response.
The only EPO-derived peptide that completely decouples tissue protection from red blood cell production — providing nerve regeneration without any hematologic effects. This distinctive profile is a key reason ARA-290 maintains its popularity despite the growing number of alternatives.
What Are the Common Criticisms?
The most common complaints about ARA-290: Safe profile in multiple clinical trials. Minimal reported adverse events. Occasional mild injection site reactions. No serious safety concerns identified across diabetes, sarcoidosis, and neuropathy patient populations.
Cost and sourcing quality are also frequent concerns — results vary significantly between vendors, which is why COA testing is essential.
How Does ARA-290 Compare to Alternatives?
As a Innate repair receptor agonist, anti-inflammatory peptide, ARA-290 competes with several similar compounds. The only EPO-derived peptide that completely decouples tissue protection from red blood cell production — providing nerve regeneration without any hematologic effects.
Synergizes with BPC-157 for comprehensive tissue repair — ARA-290 handles neuropathic and inflammatory pathways while BPC-157 targets connective tissue and gut healing.
Bottom Line: Is ARA-290 Worth It?
Based on the available research and community reports, ARA-290 is considered promising for neuropathic pain relief, inflammation reduction, nerve fiber regeneration, improved autonomic function, metabolic control in diabetes. The key factors for success: consistent dosing (2-4 mg daily once daily), quality sourcing, and realistic expectations over 28 days typical; 8-16 weeks for extended response cycles.
Complete Guide
ARA-290 : Benefits, Dosage, Side Effects & Research
Related Reading
- ARA-290 Dosage Guide
- ARA-290 Benefits
- ARA-290 Side Effects
- ARA-290 Stacking Guide
- ARA-290 Cycle Guide
- ARA-290 Research
Calculate Your ARA-290 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for ARA-290.
Open Calculator →Research-Grade Sourcing
If you're going to research ARA-290, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is ARA-290?
ARA-290 (Erythropoietin-derived tissue-protective peptide) is a Innate repair receptor agonist, anti-inflammatory peptide. Synthetic 11-amino acid peptide engineered from the tissue-protective domain of erythropoietin (EPO). It is researched for neuropathic pain relief, inflammation reduction, nerve fiber regeneration, improved autonomic function, metabolic control in diabetes.
What is the recommended ARA-290 dosage?
Common dosages: 2-4 mg daily administered once daily via subcutaneous injection. Cycle length: 28 days typical; 8-16 weeks for extended response. Half-life: approximately 24 hours. Use our peptide calculator for exact reconstitution math.
What are the side effects of ARA-290?
Safe profile in multiple clinical trials. Minimal reported adverse events. Occasional mild injection site reactions. No serious safety concerns identified across diabetes, sarcoidosis, and neuropathy patient populations.
Is ARA-290 safe?
ARA-290 has shown a preliminary safety profile in research. Investigational. Underwent Phase II clinical trials. Not FDA-approved. All research should follow appropriate safety protocols.